NeuroOne Medical Technologies (NASDAQ: NMTC) reported recent insider selling by a senior commercial executive alongside quarterly financial results and new analyst coverage.
According to a Form 4 filed with the Securities and Exchange Commission and signed by Emily Johns, by Power of Attorney, on April 1, 2026, Mark Christianson, NeuroOne’s Business Development Director, sold 15,363 shares of common stock on March 30, 2026 at $0.74 per share for a total of $11,368. The filing also shows Christianson disposed of an additional 253 shares on March 31, 2026 at $0.777 per share for $196.
After these dispositions, Christianson directly holds 198,667 shares of the company’s common stock.
The insider activity occurred as the stock was trading at $0.80, a level noted as 105% higher than the company’s 52-week low of $0.40. The filing and market data referenced analysts’ price targets that range from $1.50 to $3.00.
Additional financial context in the filings highlights operational figures referenced in third-party research: a reported negative EBITDA of $7.38 million alongside a current ratio of 6.41. The data source cited also offers supplementary analysis and ProTips available in the company’s Pro Research Report.
NeuroOne’s most recent quarterly disclosure, Q1 Fiscal 2026, showed a net loss of $1.4 million, or $0.03 per share, which was above the consensus expected loss per share of $0.04. Revenue for the quarter reached $2.9 million, slightly outpacing the forecasted $2.86 million. The earnings release was associated with activity in premarket trading.
Separately, Jones Trading initiated coverage on NeuroOne with a Buy rating and established a $1.50 price target. The research note attributed part of the company’s revenue expansion to product sales, reporting that product revenue grew from $3.5 million in fiscal 2024 to $9.1 million in fiscal 2025, driven by sales of the OneRF Ablation System.
Taken together, the insider sale, quarterly results, and new analyst coverage represent recent developments investors and market participants may evaluate when assessing NeuroOne’s near-term outlook and capital trajectory.